NeoGenomics, Inc. (NASDAQ:NEO) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, and welcome to the NeoGenomics First Quarter 2026 Financial Results Call. Please be advised that today's conference is being recorded.
Posts Tagged ‘NASDAQ:NEO’
11 Most Buzzing Stocks to Buy with the Highest Upside Potential
On March 4, Henry McVey, Head of Global Macro & Asset Allocation at KKR and CIO of the firm's balance sheet, appeared on CNBC's 'Closing Bell Overtime' to talk about the geopolitical...
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2025 Earnings Call Transcript February 17, 2026NeoGenomics, Inc. misses on earnings expectations.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2025 Earnings Call Transcript October 28, 2025NeoGenomics, Inc. misses on earnings expectations.
Here’s Alger Weatherbie Specialized Growth Fund’s Comment on NeoGenomics (NEO)
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” second-quarter 2025 investor letter.
Brown Advisory Small-Cap Growth Strategy Sold Neogenomics (NEO) Following the News of CEO Departure
Brown Advisory, an investment management company, released its "Brown Advisory Small-Cap Growth Strategy" second-quarter 2025 investor letter.
NeoGenomics (NEO) Targets Opportunity at $5 billion Liquid Biopsy Market
NeoGenomics, Inc. (NASDAQ:NEO) is one of the top 10 medical AI companies to buy according to analysts.
Top 10 Medical AI Companies to Buy According to Analysts
Artificial intelligence is transforming medical sciences in ways not seen before.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2025 Earnings Call Transcript July 29, 2025NeoGenomics, Inc. reports earnings inline with expectations.
Here’s Why NeoGenomics (NEO) Sold Off in Q1
Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 investor letter.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript April 29, 2025NeoGenomics, Inc. misses on earnings expectations.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2024 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Second Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
20 Most Profitable Stocks of the Last 20 Years
The stock market has a long history of generating wealth for investors.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript
NeoGenomics, Inc. beats earnings expectations. Reported EPS is $-0.02, expectations were $-0.03.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2023 Earnings Call Transcript
NeoGenomics, Inc. beats earnings expectations. Reported EPS is $0.03, expectations were $-0.01.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the NeoGenomics Third Quarter 2023 Earnings Call -- Third Quarter 2023 Financial Results Conference Call and Webcast.
Top 20 Genomics Companies in the World
In this piece, we will take a look at the top 20 genomics companies in the world.
NeoGenomics, Inc. (NASDAQ:NEO) Q2 2023 Earnings Call Transcript
Operator: Welcome to the NeoGenomics Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2023 Earnings Call Transcript
Operator: Welcome to the NeoGenomics First Quarter 2023 Financial Results Conference Call and Webcast. At this time all participants are in listen only mode.
NeoGenomics, Inc. (NASDAQ:NEO) Q4 2022 Earnings Call Transcript
Operator: Good morning. Welcome to the NeoGenomics Fourth Quarter and Full Year 2020 Earnings Conference Call.
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2022 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the NeoGenomics Third Quarter 2022 Earnings Call.
12 Biggest Genomics Companies In The World
In this article, we will discuss the 12 Biggest Genomics Companies In The World.
Here’s How Artisan Partners Views NeoGenomics (NEO)
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here.
Is it Still Worthy to Invest in NeoGenomics (NEO)?
Carillon Tower Advisers, an investment management firm, published its “Carillon Scout Small Cap Fund” first quarter 2022 investor letter – a copy of which can be downloaded...
Artisan Partners Remains Optimistic in NeoGenomics (NEO), Here’s Why
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded...
Is NeoGenomics (NEO) A Smart Long-Term Buy?
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ third quarter 2021 investor letter – a copy of which can be downloaded...
Artisan Partners on NeoGenomics (NEO): “We Remain Excited About the Company”
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ second quarter 2021 investor letter – a copy of which can be downloaded...
Alger Weatherbie Specialized Growth Fund: “We Believe NeoGenomics (NEO) is in the Sweet Spot”
Alger, an investment management firm, published its “Alger Weatherbie Specialized Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here...
Artisan Remains Optimistic on the Longer-Term Profit Cycle Potential of NeoGenomics (NEO)
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded...
NeoGenomics (NEO): A Genomic Stock Worth Checking?
NeoGenomics Inc. (NASDAQ:NEO), founded in 2002, runs a laboratory network across the U.S., with a prime focus on cancer genetics diagnostic testing.
Is NEO A Good Stock To Buy Now?
In this article we are going to use hedge fund sentiment as a tool and determine whether NeoGenomics, Inc. (NASDAQ:NEO) is a good investment right now.
Top 10 Healthcare Stocks To Buy for the Future
Small- and mid-cap biotech and pharmaceutical companies represent some of the most compelling gambles available on the market.
Hedge Funds Are Piling Into NeoGenomics, Inc. (NEO)
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Hedge Funds Are Souring On NeoGenomics, Inc. (NEO)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Were Dumping NeoGenomics, Inc. (NEO) Before The Coronavirus
We hate to say this but, we told you so.
Did Hedge Funds Drop The Ball On NeoGenomics, Inc. (NEO) ?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Hedge Fund and Insider Trading News: Paul Tudor Jones, Bodenholm Capital, Kingstown Capital Management, Mettler-Toledo International Inc. (MTD), AvalonBay Communities Inc (AVB), and More
Hedge-fund manager said Monday he is bullish U.S. stocks this year, noting American equities will outperform their global counterparts.
Is NeoGenomics, Inc. (NEO) Going To Burn These Hedge Funds ?
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider...
Did Hedge Funds Drop The Ball On NeoGenomics, Inc. (NEO) ?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Hedge Funds Have Never Been This Bullish On NeoGenomics, Inc. (NEO)
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to...
NeoGenomics, Inc. (NEO): Hedge Funds Are Snapping Up
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ...
Is NeoGenomics, Inc. (NEO) A Good Stock To Buy?
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions...
Do Hedge Funds Love NeoGenomics, Inc. (NEO)?
The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources...
What Sparked the Large Moves of These Five Stocks?
It's Wednesday, and shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Concordia Healthcare Corp (NASDAQ:CXRX), SanDisk Corporation (NASDAQ:SNDK), NeoGenomics, Inc.
Carl Wiese’s Grow Partners Top Picks in Q4
Carl Wiese founded Grow Partners in 2012. Wiese has more than 22 years of investment management experience.
Trius Therapeutics, Inc. (TSRX): Are Hedge Funds Right About This Stock?
Trius Therapeutics, Inc. (NASDAQ:TSRX) was in 8 hedge funds' portfolio at the end of December. TSRX has experienced a decrease in enthusiasm from smart money recently.
Hedge Fund Resource Center
